CHF-6366 is under clinical development by Chiesi Farmaceutici and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CHF-6366’s likelihood of approval (LoA) and phase transition for Asthma took place on 08 Jun 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 08 Jun 2021 decreased CHF-6366’s Phase Transition Success Rate (PTSR) for Chronic Obstructive Pulmonary Disease (COPD).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CHF-6366 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CHF-6366 overview

CHF-6366 was under development for the treatment of respiratory diseases including chronic obstructive pulmonary disease (COPD) and severe asthma. The drug candidate is a small molecule and is administered as an inhalation. It is a new chemical entity (NCE). It acts by targeting M3 muscarinic and beta 2 adrenergic receptors.

Chiesi Farmaceutici overview

Chiesi Farmaceutici (Chiesi) researches, develops, produces and commercializes novel medicines with a focus on respiratory, neonatology, rare disease and special care therapeutic areas. The company provides products for the treatment of chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis, ankylosing spondylitis, hypertension, percutaneous coronary intervention, apnoea of prematurity, respiratory distress syndrome, lipoprotein lipase deficiency (LPLD), limbal stem cell deficiency (LSCD) and inflammatory bowel diseases, among others. The company operates production sites in Parma, Italy; Blois, France; and Santana De Parnaiba, Brazil; and conducts research and development activities at its R&D center in Parma and at laboratories in Paris (France), Chippenham (the UK), Cary (the US) and Lidingo (Sweden). Chiesi is headquartered in Parma, Emilia-Romagna, Italy.

Quick View CHF-6366 LOA Data

Report Segments
  • Innovator
Drug Name
  • CHF-6366
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
Key Developers
Highest Development Stage
  • Inactive

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.